#United States #Raleigh #Everest Group #RTSM #Endpoint Clinical

Endpoint Clinical Named a Leader in 2025 Everest Group Life Sciences RTSM Products PEAK Matrix Assessment

On December 1, 2025, Endpoint Clinical earned the prestigious title of a Leader in the Everest Group's Life Sciences Randomization and Trial Supply Management (RTSM) Products PEAK Matrix Assessment. This recognition highlights Endpoint Clinical's commitment to driving innovation in clinical research, focusing on reliability, flexibility, and patient-centric outcomes.

The Everest Group PEAK Matrix is a comprehensive analytical framework that evaluates vendors in the RTSM space based on two crucial dimensions: market impact and vision & capability. The assessment of market impact takes into account several factors, including the level of adoption, the diversity of portfolios, and the overall value delivered to clients. On the other hand, vision and capability reflect the strategic direction, technological advancements, operational flexibility, engagement models, and the support services provided.

Endpoint Clinical’s accolade is a testament to its enduring focus on enhancing clinical trials and making a significant difference in patient lives. With years of expertise powering numerous studies globally, Endpoint Clinical has developed RTSM solutions designed for speed, quality, and agility. Their solutions are tailored to help bring life-saving medical therapies to market quickly and efficiently, reflecting a strong commitment to improving patient outcomes.

Nagaraja Srivatsan, CEO of Endpoint Clinical, expressed pride in this recognition, stating, "Being acknowledged as a Leader by Everest Group validates our dedication to bringing innovation in clinical trial operations through our technology, people, and exceptional service." He further emphasized that the core mission of Endpoint Clinical is the delivery of solutions that combine high quality, speed, and agility—all aimed at enhancing outcomes for both patients and sponsors alike.

The leadership position achieved by Endpoint Clinical also signifies their dedication to maintaining a patient-first approach, emphasizing tailored services and responsive support to ensure that every trial operates smoothly. This commitment is further enhanced by their incorporation of AI-driven capabilities, which refine decision-making, optimize trial operations, and strive to improve global patient outcomes.

Endpoint Clinical's innovative RTSM solutions are designed to integrate seamlessly into clinical trial processes. They provide anticipatory and adaptive solutions that help mitigate risks proactively, allowing sponsors and clinical research organizations (CROs) to concentrate on executing their studies effectively. The technology-forward orientation of Endpoint, along with its high-touch services, enables it to harness available resources efficiently to generate strategic and prompt solutions.

For readers interested in learning more about Endpoint Clinical’s RTSM offerings, further details can be found on their official website at endpointclinical.com. For those wishing to delve deeper into the insights of the Everest Group assessment and Endpoint Clinical's distinguished Leader status, the comprehensive report is accessible at everestgrp.com.

As the landscape of clinical trial management evolves, Endpoint Clinical's leadership in developing innovative solutions continues to mark them as a vital partner in clinical research, dedicated to supporting sponsors and CROs across diverse geographical regions and medical fields. This recognition by Everest Group not only affirms their status but also reinforces their mission to improve the efficiency and effectiveness of clinical trials around the world.